Ipilimumab (Yervoy) in melanoma has been approved by the FDA to include adjuvant treatment of patients with stage III melanoma who are at high risk of recurrence following complete resection.
Regulatory
FDA approves Yervoy to reduce the risk of melanoma returning after surgery
Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.
New Melanoma Drug Uses Tumor-Busting Virus
The Food and Drug Administration approved a new drug Tuesday that uses a genetically engineered cold sore virus to bust up melanoma skin cancer tumors.
It’s the first drug of its type to get FDA approval. It’s made using a genetically engineered herpes virus — the same kind that causes cold sores — that carries an immune system compound into tumors, causing them to burst apart.
The drug, called Imlygic, doesn’t cure the patient and it has not been shown to help patients live longer, But it provides relief from melanoma, the deadliest form of skin cancer.
FDA Approves Combination Therapy For BRAF Wild-Type Unresectable or Metastatic Melanoma
Bristol-Myers Squibb recently announced the approval by the U.S. Food and Drug Administration (FDA) of its combination therapy, Opdivo (nivolumab) with Yervoy (ipilimumab), for BRAF V600 wild-type unresectable or metastatic melanoma. This is the first combination therapy of two immuno-oncology drugs approved by the FDA.